Technology · The hall
A $95 million genome, for $525
NHGRI tracked the all-in cost of sequencing a human-sized genome from $95.3 million in 2001 to $525 in May 2022. That is a 181,000-fold collapse — faster than Moore’s law by more than two orders of magnitude. Biology became a compute problem while we were watching chips.
- NHGRI cost per genome, May 2022
- $525
- September 2001
- $95.3m
- Cheaper in 21 years
- 181,000×
- The year next-gen sequencing broke the line
- 2008
The steepest industrial price collapse we have a ledger for
NHGRI has published the all-in cost of sequencing a human-sized genome at the centres it funds since 2001. September 2001: $95,263,072. May 2022: $525. That is a 181,000-fold reduction in twenty-one years. Moore’s law, generously applied, is about a hundred-fold in the same window. The chart is unreadable on a linear axis, which is the point — use the log toggle. The 2008 cliff is next-generation sequencing arriving at the NIH pipeline: October 2008 is $165,047, down from $10.4 million the year before. 2015 is the public ‘$1,000 genome’ (the print is $1,363, then $1,241). After 2018 the line flattens. The miracle already happened.
$200 is a slide. $525 is a spreadsheet
Illumina’s NovaSeq X marketing talks about a $200 genome. That is reagents on a full flow cell, not the NHGRI all-in series (labour, instruments, informatics, sample prep). We do not plot it. Pair this with Five times more compute, every year and The shot that bent the curve. Cheap letters in a genome are an input to GLP-1 target discovery, to cancer panels, to the same intelligence infrastructure that is eating electricity. Biology became a data centre with a pipette.
The long view is a commodity, then a bottleneck
Once a genome is $525, sequencing is not the scarce step. Interpretation, clinical action, and the legal permission to use the file are. The investing error of 2012 was to ignore the curve. The investing error of 2026 is to own another sequencer and call it a platform. Own the applications that compound on a $525 input — oncology, rare disease, the metabolic drugs — and the compute that reads the letters. Do not own a 2001 mental model.
Investing lens
Horizon 5–15 years · Educational, not advice
The price collapse is done. The investable question is who uses a $525 genome as an input, not who sells another 30× run. Diagnostics with reimbursement, the drug pipelines that need the file, and the compute around it.
Where the map points
- Clinical NGS with payer coverage, not research-only volume
- Oncology and rare-disease franchises that actually use the file
- The compute and storage around interpretation
- Avoid a $200-reagent story as if it were NHGRI accounting
What can break it
- The NHGRI series stopped in 2022 — later prices are marketing
- Reimbursement, not chemistry, gates clinical volume
- A sequencer price war that looks like solar modules
CHART does not recommend securities, funds or trades. Figures can be revised by their publishers. Do your own research and consider regulated advice before allocating capital.
Sources
Every headline number traces to a named publisher. Contextual sources inform the essay, not the key stat.
- 01PrimaryNational Human Genome Research Institute2023-05DNA Sequencing Costs: Data
All-in cost per human-sized genome at NHGRI-funded centres. September 2001 $95,263,072; May 2022 $525. Series not updated past May 2022. Illumina $200 claims are reagent list, not this accounting.
- 02PrimaryEpoch AI2026-02-05Trends in Artificial Intelligence
Training compute for frontier language models has been growing at 5× per year since 2020 (doubling every 5.2 months; 0.7 OOM/year).
Keep reading
Five times more compute, every year
Epoch AI: training compute for frontier language models has grown 5× per year since 2020 — a doubling every 5.2 months. That is not Moore’s law. That is a wartime production curve wearing a research-lab badge.
5×/yr
Frontier training compute since 2020
The first drug class to bend obesity
Obesity medicines did $66 billion of list-price business in 2025. IQVIA sees $92 billion this year. WHO still expects the condition to double by 2030 — and the shots to reach fewer than one in ten who need them.
$66bn
Obesity-medicine sales, 2025
The cheapest electron in history
Utility-scale solar now costs $44 per megawatt-hour. In 2010 it was about $445. That is a 90% collapse in fourteen years — the steepest learning curve of any energy technology we have a number for.
$44
Solar PV LCOE, 2025 (IRENA)